Century Therapeutics (IPSC) Preferred Stock Liabilities (2020 - 2021)
Century Therapeutics (IPSC) posted quarterly Preferred Stock Liabilities of $159.6 million for Q1 2021, up 357.1% quarter-over-quarter from $34.9 million in Q4 2020.
Century Therapeutics (IPSC) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Century Therapeutics (IPSC) has reported Preferred Stock Liabilities for 2 consecutive years, with $159.6 million the latest figure, recorded in Q1 2021.
- In Q1 2021, Preferred Stock Liabilities changed N/A year-over-year to $159.6 million; the TTM figure through Mar 2021 stood at $159.6 million (changed N/A YoY), while the FY2020 annual figure was $34.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities rose to $159.6 million in Q1 2021 per IPSC's latest filing, from $34.9 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $159.6 million in Q1 2021 and bottomed at $34.9 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Century Therapeutics | 346.65 Mn | 86.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 159.63 Mn |
| Dec 31, 2020 | 34.92 Mn |
| Sep 30, 2020 | 34.99 Mn |
| Jun 30, 2020 | 34.99 Mn |